FWIW, Which I Fear Is Precious Little...
Last week, I sent an e-mail to Pharmos asking a question
that was personally important to me about any possible HU-211
applications for post-polio... because my brother suffers from this
degenerative condition.
Within two days, Gad Reisenfeld, responded with, in part,
this message...
"... Dexanabinol is a broad-based neuroprotectant and anti-inflammatory. It has shown neuroprotection in many animal models for potentially various
indications. We also test many analogs for other potential neurological indications. It will take, however, many years to develop the products and there is no guarantee of success. I cannot comment specifically on ALS and post-polio applications."
While, for sure, this tells INVESTORS nothing new, I respect
the company's prompt response to my question. Further, I respect
the fact that Gad was very circumspect in his answer about possible
indications for HU-211. Not particularly heartening for my brother,
but... what can you say?
Best Regards, PARSians
c m
|
